Literature DB >> 30590592

Remembering the Host in Tuberculosis Drug Development.

Daniel J Frank1, David J Horne2, Noton K Dutta3, Moagi Tube Shaku4, Rajhmun Madensein5, Thomas R Hawn2, Adrie J C Steyn6,7, Petros C Karakousis3, Bavesh Davandra Kana4,8, Graeme Meintjes9,10, Barbara Laughon11,12, Zaid Tanvir12,13.   

Abstract

New therapeutics to augment current approaches and shorten treatment duration are of critical importance for combating tuberculosis (TB), especially those with novel mechanisms of action to counter the emergence of drug-resistant TB. Host-directed therapy (HDT) offers a novel strategy with mechanisms that include activating immune defense mechanisms or ameliorating tissue damage. These and related concepts will be discussed along with issues that emerged from the workshop organized by the Stop TB Working Group on New Drugs, held at the Gordon Research Conference for Tuberculosis Drug Development in Lucca, Italy in June 2017, titled "Strategic Discussion on Repurposing Drugs & Host Directed Therapies for TB." In this review, we will highlight recent data regarding drugs, pathways, and concepts that are important for successful development of HDTs for TB.
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  drug development; host-directed therapy; macrophage; meningitis; tuberculosis

Mesh：

Substances：

Year:  2019        PMID： 30590592      PMCID： PMC6562157          DOI： 10.1093/infdis/jiy712

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  50 in total

1.  Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections.

Authors:  David M Tobin; Francisco J Roca; Sungwhan F Oh; Ross McFarland; Thad W Vickery; John P Ray; Dennis C Ko; Yuxia Zou; Nguyen D Bang; Tran T H Chau; Jay C Vary; Thomas R Hawn; Sarah J Dunstan; Jeremy J Farrar; Guy E Thwaites; Mary-Claire King; Charles N Serhan; Lalita Ramakrishnan
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

2.  Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

Authors:  Ciaran Skerry; Michael L Pinn; Natalie Bruiners; Richard Pine; Maria L Gennaro; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2014-05-22       Impact factor: 5.790

3.  Host sirtuin 1 regulates mycobacterial immunopathogenesis and represents a therapeutic target against tuberculosis.

Authors:  Catherine Y Cheng; Nuria M Gutierrez; Mardiana B Marzuki; Xiaohua Lu; Taylor W Foreman; Bhairav Paleja; Bernett Lee; Akhila Balachander; Jinmiao Chen; Liana Tsenova; Natalia Kurepina; Karen W W Teng; Kim West; Smriti Mehra; Francesca Zolezzi; Michael Poidinger; Barry Kreiswirth; Deepak Kaushal; Hardy Kornfeld; Evan W Newell; Amit Singhal
Journal:  Sci Immunol       Date:  2017-03-24

4.  Metformin as adjunct antituberculosis therapy.

Authors:  Amit Singhal; Liu Jie; Pavanish Kumar; Gan Suay Hong; Melvin Khee-Shing Leow; Bhairav Paleja; Liana Tsenova; Natalia Kurepina; Jinmiao Chen; Francesca Zolezzi; Barry Kreiswirth; Michael Poidinger; Cynthia Chee; Gilla Kaplan; Yee Tang Wang; Gennaro De Libero
Journal:  Sci Transl Med       Date:  2014-11-19       Impact factor: 17.956

5.  Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study.

Authors:  Mark R Albertella; Paul M Loadman; Philip H Jones; Roger M Phillips; Roy Rampling; Neil Burnet; Chris Alcock; Alan Anthoney; Egils Vjaters; Chris R Dunk; Peter A Harris; Alvin Wong; Alshad S Lalani; Chris J Twelves
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

6.  Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon γ-producing T cells from apoptosis in patients with pulmonary tuberculosis.

Authors:  Amar Singh; Anant Mohan; Aparajit B Dey; Dipendra K Mitra
Journal:  J Infect Dis       Date:  2013-05-09       Impact factor: 5.226

7.  Inflammasome Activation Underlying Central Nervous System Deterioration in HIV-Associated Tuberculosis.

Authors:  Suzaan Marais; Rachel P J Lai; Katalin A Wilkinson; Graeme Meintjes; Anne O'Garra; Robert J Wilkinson
Journal:  J Infect Dis       Date:  2017-03-01       Impact factor: 5.226

Review 8.  Tuberculous meningitis.

Authors:  Robert J Wilkinson; Ursula Rohlwink; Usha Kant Misra; Reinout van Crevel; Nguyen Thi Hoang Mai; Kelly E Dooley; Maxine Caws; Anthony Figaji; Rada Savic; Regan Solomons; Guy E Thwaites
Journal:  Nat Rev Neurol       Date:  2017-09-08       Impact factor: 42.937

9.  Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome.

Authors:  Suzaan Marais; Graeme Meintjes; Dominique J Pepper; Lori E Dodd; Charlotte Schutz; Zahiera Ismail; Katalin A Wilkinson; Robert J Wilkinson
Journal:  Clin Infect Dis       Date:  2012-10-24       Impact factor: 9.079

Review 10.  Corticosteroids for managing tuberculous meningitis.

Authors:  Kameshwar Prasad; Mamta B Singh; Hannah Ryan
Journal:  Cochrane Database Syst Rev       Date:  2016-04-28
View more
  13 in total

1.  Adjunctive Host-Directed Therapy With Statins Improves Tuberculosis-Related Outcomes in Mice.

Authors:  Noton K Dutta; Natalie Bruiners; Matthew D Zimmerman; Shumin Tan; Véronique Dartois; Maria L Gennaro; Petros C Karakousis
Journal:  J Infect Dis       Date:  2020-03-16       Impact factor: 5.226

2.  Editorial: Alternative Therapeutics Against Antimicrobial-Resistant Pathogens.

Authors:  Rebecca Thombre; Kamlesh Jangid; Ravi Shukla; Noton Kumar Dutta
Journal:  Front Microbiol       Date:  2019-09-19       Impact factor: 5.640

3.  FX11 limits Mycobacterium tuberculosis growth and potentiates bactericidal activity of isoniazid through host-directed activity.

Authors:  Gopinath Krishnamoorthy; Peggy Kaiser; Ulrike Abu Abed; January Weiner; Pedro Moura-Alves; Volker Brinkmann; Stefan H E Kaufmann
Journal:  Dis Model Mech       Date:  2020-03-30       Impact factor: 5.758

Review 4.  Mycobacterium tuberculosis Shikimate Pathway Enzymes as Targets for the Rational Design of Anti-Tuberculosis Drugs.

Authors:  José E S Nunes; Mario A Duque; Talita F de Freitas; Luiza Galina; Luis F S M Timmers; Cristiano V Bizarro; Pablo Machado; Luiz A Basso; Rodrigo G Ducati
Journal:  Molecules       Date:  2020-03-11       Impact factor: 4.411

5.  Small Animal Models for Human Immunodeficiency Virus (HIV), Hepatitis B, and Tuberculosis: Proceedings of an NIAID Workshop.

Authors:  Ramesh Akkina; Daniel L Barber; Moses T Bility; Karl-Dimiter Bissig; Benjamin J Burwitz; Katrin Eichelberg; Janice J Endsley; J Victor Garcia; Richard Hafner; Petros C Karakousis; Brent E Korba; Rajen Koshy; Chris Lambros; Stephan Menne; Eric L Nuermberger; Alexander Ploss; Brendan K Podell; Larisa Y Poluektova; Brigitte E Sanders-Beer; Selvakumar Subbian; Angela Wahl
Journal:  Curr HIV Res       Date:  2020       Impact factor: 1.581

Review 6.  The New Frontier of Host-Directed Therapies for Mycobacterium avium Complex.

Authors:  Nathan P Crilly; Samuel K Ayeh; Petros C Karakousis
Journal:  Front Immunol       Date:  2021-01-22       Impact factor: 7.561

7.  Inhibition of the PERK/TXNIP/NLRP3 Axis by Baicalin Reduces NLRP3 Inflammasome-Mediated Pyroptosis in Macrophages Infected with Mycobacterium tuberculosis.

Authors:  Yan Fu; Jingjing Shen; Yinhong Li; Fanglin Liu; Bangzuo Ning; Yuejuan Zheng; Xin Jiang
Journal:  Mediators Inflamm       Date:  2021-11-08       Impact factor: 4.711

8.  Are There Sex-Specific Differences in Response to Adjunctive Host-Directed Therapies for Tuberculosis?

Authors:  Noton K Dutta; Bianca E Schneider
Journal:  Front Immunol       Date:  2020-07-07       Impact factor: 7.561

9.  Harnessing the Immunomodulatory Properties of Bacterial Ghosts to Boost the Anti-mycobacterial Protective Immunity.

Authors:  Jieling Lim; Vanessa Hui Qi Koh; Sharol Su Lei Cho; Balamurugan Periaswamy; Dawn Poh Sum Choi; Maurizio Vacca; Paola Florez De Sessions; Pavol Kudela; Werner Lubitz; Giorgia Pastorin; Sylvie Alonso
Journal:  Front Immunol       Date:  2019-11-22       Impact factor: 7.561

10.  Type I interferon signaling mediates Mycobacterium tuberculosis-induced macrophage death.

Authors:  Li Zhang; Xiuju Jiang; Daniel Pfau; Yan Ling; Carl F Nathan
Journal:  J Exp Med       Date:  2021-02-01       Impact factor: 17.579
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.